Comparative Pharmacology
Head-to-head clinical analysis: CORVERT versus DRONEDARONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORVERT versus DRONEDARONE.
CORVERT vs DRONEDARONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibutilide, a class III antiarrhythmic agent, prolongs atrial and ventricular refractoriness by blocking delayed rectifier potassium current (IKr) and activating slow inward sodium current (INa-S).
Dronedarone is a multichannel blocker that inhibits potassium (IKr, IKs, IKur), sodium (INa), and calcium (ICaL) currents, and exhibits antiadrenergic effects via noncompetitive antagonism of beta-1 and beta-2 receptors. It also prolongs atrial refractoriness and slows atrioventricular conduction.
1 mg intravenously over 10 minutes; repeat once after 10 minutes if conversion to sinus rhythm not achieved. Maximum total dose: 2 mg.
400 mg orally twice daily after meals
None Documented
None Documented
Clinical Note
moderateDronedarone + Levofloxacin
"Dronedarone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateDronedarone + Norfloxacin
"Dronedarone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDronedarone + Gemifloxacin
"Dronedarone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateDronedarone + Ibandronate
"Dronedarone may increase the QTc-prolonging activities of Ibandronate."
Terminal elimination half-life is approximately 6 hours (range 2–12 hours) in patients with normal renal function. Prolonged in renal impairment (up to 16 hours in severe impairment).
Terminal half-life is 13–19 hours; steady state achieved within 4–8 days.
Renal (approximately 82% of total clearance), with about 18% biliary/fecal elimination. Mostly unchanged drug and metabolites.
Primarily fecal (≥84%) via biliary excretion; renal excretion accounts for <6% as unchanged drug.
Category C
Category C
Antiarrhythmic
Antiarrhythmic